Christina Kile, MD
Endocrinology, Diabetes & Metabolism · Albany, GANPI 1326072851
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 68.1% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2019 at $5,073 and has fallen 78.0% since, to $1,116 in 2025.
Across 182 payments — averaging $61.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Amgen$778
- Novo Nordisk$638
- Medtronic$376
- Astellas Pharma US Inc$267
- Johnson & Johnson$152
- plus $1K from 29 others
What the payments were for
- Speaking & faculty fees$5,70051%
- Travel & lodging$1,64915%
- Food & beverage$3,78634%
- Education$801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $7,636 |
| Amgen(2 entities) | 42 | $778 |
| Novo Nordisk | 38 | $638 |
| Medtronic | 9 | $376 |
| Astellas Pharma US Inc | 14 | $267 |
| Johnson & Johnson | 6 | $152 |
| Sanofi-aventis U.S. LLC | 9 | $146 |
| Xeris Pharmaceuticals, Inc. | 1 | $146 |
| Abbott | 6 | $112 |
| Lilly USA, LLC | 7 | $101 |
| Radius Health, Inc. | 5 | $93 |
| Ultragenyx Pharmaceutical Inc. | 4 | $88 |
| Bayer | 5 | $86 |
| Corcept Therapeutics | 1 | $86 |
| Ascendis Pharma Endocrinology Inc | 1 | $80 |
| Dexcom, Inc. | 3 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Exact Sciences | 2 | $32 |
| Rhythm Pharmaceuticals, Inc. | 1 | $31 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Irhythm Technologies, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Valeritas, Inc. | 1 | $12 |
| AstraZeneca | 1 | $12 |
| BETA Bionics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Synthroid$7,463
- MINIMED 780G$304
- RECORLEV$146
- EVENITY$100
How this compares
$11,215 in reported general payments places this provider in the 80th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 260 | $385,544 |
| MiacalcinCalcitonin,salmon,synthetic | 15 | $328,871 |
| JardianceEmpagliflozin | 149 | $199,457 |
| MounjaroTirzepatide | 146 | $156,077 |
| TrulicityDulaglutide | 62 | $85,785 |
| RybelsusSemaglutide | 46 | $80,144 |
| FarxigaDapagliflozin Propanediol | 70 | $79,225 |
| SynthroidLevothyroxine Sodium | 673 | $69,966 |
| Cinacalcet Hcl | 84 | $34,808 |
| ProliaDenosumab | 16 | $27,063 |
| GenotropinSomatropin | 14 | $25,830 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $22,665 |
| JanuviaSitagliptin Phosphate | 20 | $20,256 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 21 | $18,206 |
| InvokanaCanagliflozin | 15 | $12,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $638 | $465,689306 claims |
| Lilly USA, LLCMounjaro, Trulicity | $101 | $241,862208 claims |
| AstraZenecaFarxiga | $12 | $79,22570 claims |
| AbbVieSynthroid, Armour Thyroid | $7,636 | $71,961696 claims |
| AmgenProlia | $778 | $27,06316 claims |
| Johnson & JohnsonInvokana | $152 | $12,48615 claims |
| BayerKerendia | $86 | $9,55315 claims |
| IBSA Pharma Inc.Tirosint | $18 | $2,57011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Albany
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
- Naland ShenoySnellville$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.